559 results about "Neuroinflammation" patented technology

The invention discloses bifidobacterium breve and application thereof in relieving Alzheimer's disease, and belongs to the technical field of probiotics. The preparation method comprises the following steps: separating 18 bifidobacterium strains from feces of children aged 0-3 years old, analyzing and identifying the 18 bifidobacterium strains including bifidobacterium longum, bifidobacterium breve and bifidobacterium animalis, and screening out the bifidobacterium breve LE4 with potential Alzheimer's disease relieving capacity through in-vitro oxidation resistance and LPS (Lipopolysaccharide) removal capacity. The method comprises the steps of behavioral experiments (nesting experiments, open field experiments and water maze experiments), histopathologic analysis, molecular biological detection and the like. The multi-target AD intervention effects of improving the cognitive function, reducing A beta deposition and tau protein phosphorylation, relieving neuroinflammation, enhancing synaptic plasticity, repairing intestinal barriers, adjusting intestinal flora and metabolites and the like of the LE4 strain are comprehensively evaluated, and a new strategy is provided for promoting AD micro-ecological treatment.

The invention relates to the field of biological imaging, and particularly discloses an in-vitro cell microenvironment dynamic monitoring method for two-photon frequency domain fluorescence lifetime imaging, which comprises the following steps: S1, by using a two-photon frequency domain fluorescence lifetime imaging TP-FD-FLIM technology, losslessly representing microenvironment change through fluorescence lifetime parameters, and monitoring oxidative stress reaction and neutrophil migration behavior in real time, analyzing the effect of the associated compound in combination with an in-vitro cell model; and S2, based on the physical basis of FD-FLIM, establishing a frequency domain fluorescence lifetime signal processing and analysis system under periodic excitation, analyzing the dynamic correlation characteristics of the phase delay phi and the modulation depth M of a fluorescence signal relative to exciting light, and carrying out quantitative backstepping on molecular lifetime parameters. According to the in-vitro cell microenvironment dynamic monitoring method for two-photon frequency domain fluorescence lifetime imaging provided by the invention, neuroinflammatory response can be observed in a lossless and real-time manner on the subcellular scale.

The invention discloses an intestinal bacterial composition for improving a cognitive function and relieving neuroinflammation and an application of the intestinal bacterial composition, and belongs to the technical field of biomedicine and microbiology, the intestinal bacterial composition is composed of a Lachnospiraceae bacterium, a Bacteroides multiforme and a Roseburiatestinae bacterium, and the intestinal bacterial composition is prepared from the following raw materials of the following raw materials of the intestinal bacterial composition: the Lachnospiraceae bacterium, the Bacteroides multiforme and the Roseburiatestinae bacterium, the Roseburiatestinae bacterium, the Roseburiatestinae bacterium, the Roseburiatestinae bacterium, the Roseburiatestinae bacterium, the Roseburiatestinae bacterium and the like. Experimental research results show that a modular synergistic effect exists among the helicobacter hirsuticus, the bacteroides multiforme and the Roche enterobacter, and the pharmaceutical composition has a remarkable neuroprotective effect on a cognitive impairment mouse model and an Alzheimer disease mouse model, can improve the cognitive function and relieve neuroinflammation, and can be used for preparing a neuroprotective agent for treating the cognitive impairment mouse model and the Alzheimer disease mouse model. A new thought and method can be provided for treatment of cognitive impairment related diseases and neuroinflammation related diseases.

The invention discloses a mesenchymal stem cell membrane bionic nano-enzyme for targeted therapy of Parkinson's disease as well as a preparation method and application of the mesenchymal stem cell membrane bionic nano-enzyme. The mesenchymal stem cell membrane bionic nano enzyme comprises an inner core and a mesenchymal stem cell membrane, wherein the inner core is composed of mesoporous polydopamine nanoparticles, and the mesenchymal stem cell membrane coats the inner core. The medicine contains the mesenchymal stem cell membrane bionic nano enzyme. The mesenchymal stem cell membrane bionic nano-enzyme disclosed by the invention shows good biocompatibility, and can be homed to a Parkinson disease region in the brain under the mediation of CXCR4 and VLA-4 specific membrane proteins. In addition, through the CD47 membrane protein expressed on the surface, the removal of the immune system can be avoided, so that the action time in the body is prolonged. The nano-enzyme is helpful for eliminating reactive oxygen free radicals, reducing oxidative stress level and reducing damage of neuroinflammation to dopaminergic neurons, so that safe and efficient treatment of Parkinson's disease is realized.

The invention relates to the technical field of biological medicines, in particular to Hangzhou white chrysanthemum-derived exosome-like nano-vesicles as well as a preparation method and application thereof. Chrysanthemum morifolium ramat nano-vesicles are prepared from compositae plants through a high-speed centrifugation method, the average particle size of the nano-vesicles is 68 nm, and the Zeta potential is-19.50 + / -1.10 mV. The nano vesicles can effectively protect nerve cells and improve anxiety behaviors and cognitive impairment of SAE mice. The compound has a good application prospect in preparation of medicines for treating neuroinflammation and SAE.

The invention discloses preparation and application of dual-network hydrogel. The dual-network hydrogel comprises the following components: (Z1) a spinal cord acellular matrix network DSM formed by self-assembly of a spinal cord acellular matrix dSECM; and (Z2) a metal-polyphenol network MPN formed by coordination of metal ions and polyphenols; wherein the DSM and the MPN are cross-linked through hydrogen bonds to jointly form a double-network structure. DSM provides a microenvironment suitable for cell survival and growth for the dual-network hydrogel and induces stem cells to differentiate into neurons, and MPN provides the dual-network hydrogel with biological effects of inhibiting inflammation and accumulation of reactive oxygen species (ROS). The dual-network hydrogel has the advantages of the two components, the active component neurotrophic factor and the inhibitor loaded on the dual-network hydrogel can regulate and control immune response after SCI, improve neuroinflammation microenvironment and promote nerve repair, and a new strategy is provided for in-situ tissue repair of SCI.

The invention discloses application of a plant lactobacillus CCFM1357 to conversion of anthocyanin to generate various active metabolites, inhibition of a cGAS-STING pathway and enhancement of improvement of brain aging, and belongs to the technical field of microorganisms and the technical field of medicines. The phytobacterium plantarum CCFM1357 fermented anthocyanin and the compound preparation thereof provided by the invention have the following effects: (1) a marker for relieving D-gal induced mouse brain senescence and a marker for relieving D-gal induced mouse brain senescence; (2) promoting and relieving D-gal induced mouse histopathologic characterization; (3) relieving D-gal induced mouse neuroinflammation; (4) relieving behavioral characterization of the D-gal induced aging mouse; and (5) a cGAS-STING signal channel is inhibited. The phytobacterium plantarum CCFM1357 fermented anthocyanin and the compound preparation thereof provided by the invention can be used for a product for relieving brain aging, and have a huge application prospect.

The invention discloses a TREM-1 inhibitory peptide nano-particle which is prepared by the following steps: by taking a dendritic polymer PAMAM as a carrier, coupling a TREM-1 inhibitory peptide with amino groups on the carrier by utilizing the characteristic of polyamino groups on the surface of the PAMAM, and coupling a brain-targeted peptide with the other part of amino groups on the carrier through MAL-PEG2000-NHS, so as to obtain the TREM-1 inhibitory peptide nano-particle. And modifying the residual amino groups on the carrier with PEG (Polyethylene Glycol) to obtain the nano-particles. The nanoparticles can relieve encephaledema, neuroinflammation injury and blood brain barrier damage caused by traumatic craniocerebral injury, improve cognitive impairment and long-term prognosis after trauma, and have a very high curative effect on clinical treatment of craniocerebral injury.

The invention relates to the field of chemical analysis, and particularly discloses a method for detecting indole and derivatives thereof in serum and excrement. Before liquid chromatography-mass spectrometry detection, a methanol-water mixed solvent is adopted for extraction, and freeze grinding, ultrasonic treatment, standing, centrifugation and other steps are carried out. According to the pretreatment process, the influences of complex matrixes and more interfering substances are eliminated, more tryptophan metabolites are detected at the same time, the adopted pretreatment mode is simple, low in cost and environmentally friendly, and qualitative and quantitative detection of indole and derivatives thereof in complex biological samples can be achieved. The indole derivative has important significance in the fields of enhancing the integrity of the intestinal epithelial barrier, inhibiting neuroinflammation, improving insulin resistance and regulating and controlling the polarization direction of immune cells based on deep research of indole and the indole derivative.

The invention discloses design and synthesis of a series of brain-targeted ginsenoside Rg1 derivatives and application of the brain-targeted ginsenoside Rg1 derivatives in treatment of Alzheimer's disease. According to the invention, ginsenoside Rg1 and polyethylene glycol with a specific chain length are covalently linked to successfully construct the derivative capable of enhancing the penetrating power of the blood-brain barrier. The series of derivatives provided by the invention not only solve the problems of poor brain targeting and insufficient stability of natural Rg1, but also can inhibit neuroinflammation by regulating and controlling an NLRP3 / caspase-1 signal channel in an LPS-induced neuroinflammation model, and finally, the learning and memory ability is remarkably improved. The product is simple and convenient in preparation process and good in biological safety, and a new candidate compound is provided for developing a new generation of Alzheimer disease treatment medicines.

A Bifidobacterium animalis subsp. lactis for reducing Abeta42 deposition and an application, a name of the Bifidobacterium animalis subsp. lactis is Bifidobacterium animalis subsp. lactis IOB-LO7, and classified as Bifidobacterium animalis subsp. lactis, the Bifidobacterium animalis subsp. lactis IOB-LO7 is preserved in the General Microbiology Center of the China General Microbiological Culture Collection Center (CGMCC) on Dec. 23, 2021, with the collection number of CGMCC No. 24185. By reducing the levels of Aβ42 in the cerebral cortex and hippocampus, clearing Aβ amyloid plaques, improving communication between neurons, reducing brain neuroinflammation, and protecting nerve cells, it helps to restore cognitive function and improve Alzheimer's disease. Additionally, it can also improve gut microbiota imbalance caused by Alzheimer's disease.

The invention relates to a probiotic preparation for improving Parkinson's disease and an application of the probiotic preparation. The bacterial strains in the probiotic preparation comprise an Ackermania muciniphila Akk11 bacterial strain and a Bifidobacterium breve BBr60 bacterial strain. The invention further relates to a preparation method of the probiotic preparation for improving the Parkinson's disease and an application of the probiotic preparation for improving the Parkinson's disease, wherein the bacterial strains in the probiotic preparation comprise the Ackermania muciniphila Akk11 bacterial strain and the Bifidobacterium breve BBr60 bacterial strain. The invention develops a brand-new probiotic compounding mode and a brand-new probiotic intervention strategy for improving the Parkinson's disease, that is, the Akk11 strain and the BBr60 strain are compounded, and the two strains are found to have potential interaction and can be matched with each other, so that a synergistic effect is achieved on the aspect of improving the Parkinson's disease, and the effect of improving the Parkinson's disease is achieved. Specifically, the traditional Chinese medicine composition synergistically improves dyskinesia caused by Parkinson's disease, reduces expression of related inflammatory factors in nigra, promotes generation of anti-inflammatory factors to relieve neurological inflammation, inhibits activation of inflammasome NLPR3 in nigra, and further inhibits brain inflammation.

The invention relates to the technical field of plant extracts, and provides a plant extract composition with synergistic hypoglycemic activity and application thereof, and the plant extract composition comprises a mulberry leaf extract, a white kidney bean extract and bitter gourd powder in a mass ratio of 8: (1-24): (1-64). By optimizing the mass ratio of the mulberry leaf extract, the white kidney bean extract and the bitter gourd powder, the blood sugar reducing effect of the plant extract taking the mulberry leaf extract, the white kidney bean extract and the bitter gourd powder as main raw materials is remarkably superior to that of a plant extract in the prior art. Meanwhile, the plant extract composition also has the effects of synergistically reducing the number of neutrophils around nerves, improving peripheral neuroinflammation, synergistically enhancing the fluorescence intensity of the peripheral nerves, improving peripheral nerve injury and inhibiting the enzymatic activity of a bacterium source dipeptidyl peptidase-4.

The present invention features compositions and methods for preventing or treating neuroinflammation, amyloidopathy or tauopathy by inhibiting Acyl-CoA:Cholesterol Acyltransferase activity, in particular with brain-permeable inhibitors encapsulated in a stealth liposome-based nanoparticle. Stealth liposome-based nanoparticles for reducing or attenuating amyloidopathy or tauopathy are also provided.

The invention discloses application of a traditional Chinese medicine composition in preparation of a medicine for relieving side effects of oxaliplatin chemotherapy. The traditional Chinese medicine composition composed of radix paeoniae alba and liquorice is used for relieving various side reactions caused by oxaliplatin, wherein the side reactions comprise peripheral neurotoxicity, hematological toxicity and systemic reaction. The traditional Chinese medicine composition plays a role in relieving peripheral neurotoxicity caused by oxaliplatin through multiple ways, on one hand, neuroinflammatory response in dorsal root ganglions is inhibited, the dorsal root ganglions are responsible for receiving and conducting sensory nerve impulse, the injury is mainly represented as sensory disorders such as numbness of hands and feet, stabbing pain and delayed feeling, and on the other hand, the neuroinflammatory response in the dorsal root ganglions is inhibited; therefore, OIPN can be relieved by inhibiting the inflammatory reaction; on the other hand, the blood flow of microvessels is promoted, and the circulation disorder of the microvessels at the tail ends of the limbs is improved to relieve OIPN. Moreover, the traditional Chinese medicine composition does not influence the anti-tumor effect of oxaliplatin, is good in safety, and does not damage important organs such as heart, liver, spleen, lung and kidney.

The present application relates to a diacetylene compound represented by formula (I), or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising same, and a use of the compound, the pharmaceutically acceptable salt thereof, and the pharmaceutical composition. The compound, or the pharmaceutically acceptable salt thereof and the pharmaceutical composition comprising same can be used for preparing a drug for treating or relieving neuroinflammation and neurodegenerative diseases.

The invention provides an application of gastrodin in preparation of a medicine for treating peripheral neuropathy. According to the application disclosed by the invention, gastrodin can inhibit neuroinflammation mediated by microglia by inhibiting activation of an NF-kB / NLRP3 inflammasome signal channel, so that release of inflammatory factors is reduced, and neuropathy induced by bortezomib is relieved.

The invention relates to the technical field of skin care products, in particular to a stress relieving composition containing camellia flower extract and application of the stress relieving composition. The composition comprises the following components: a camellia extract, a porphyridium extract, an anise leaf extract and a vetiver extract, and the four components cooperate to regulate and control, completely intervene in a neuroinflammation path, block transmission of nerve stimulation signals, reduce release of neuropeptides and inflammatory factors, repair damaged nerve barriers and improve neurological function. The effect of comprehensively relieving the skin sensitivity reaction is achieved. The composition not only has a faster and more durable effect, but also has good safety and applicability, and is especially suitable for protecting and conditioning high-sensitivity skin and skin in an extreme environment.

The invention discloses a composition based on the synergistic effect of an SOD-LF covalent conjugate and neuromodulation and application of the composition in preparation of drugs for relieving anxiety and insomnia and improving sleep quality, and belongs to the technical field of biology. The preparation method comprises the following steps: preparing an SOD-LF covalent conjugate from lactoferrin and SOD; uniformly dispersing the SOD-LF covalent conjugate in a sodium alginate solution, spraying into a calcium chloride solution, standing, and filtering to obtain a sodium alginate coated SOD-LF covalent conjugate; and dispersing the sodium alginate coated SOD-LF covalent conjugate and fucoidin in a chitosan solution, adding sodium tripolyphosphate, stirring for reaction, and centrifugally collecting to obtain the composition based on the synergistic effect of the SOD-LF covalent conjugate and nerve regulation. According to the composition disclosed by the invention, the blood brain barrier transmittance is enhanced through the SOD-LF covalent conjugate, and the fucoidin is combined to regulate the intestinal flora-enteric brain axis to synergistically inhibit neuroinflammation and oxidative stress, so that anxiety and insomnia are improved.

The present disclosure relates to compositions and methods of treating stroke, reducing neuroinflammation, and generating new neurons in a primate using an adeno-associated viral (AAV) vector encoding NeuroD1.

The invention belongs to the field of application materials, and particularly relates to Ber-ApoEVs and preparation and application thereof.The Ber-ApoEVs comprise ApoEVs and Ber supported by the ApoEVs, the ApoEVs are bone marrow mesenchymal stem cell-derived apoptosis vesicles, and the Ber is berberine and a derivative thereof. Researches show that brand new Ber-ApoEVs play a synergistic neuroprotective role in the aspects of regulating and controlling polarization of microglial cells, release of inflammatory factors, p38 / MAPK signals and the like, neuroinflammation caused by retinal ischemia reperfusion (IR) can be relieved, retinal neuron apoptosis can be inhibited, and the Ber-ApoEVs can be used for treating glaucoma.

The invention discloses a strain for preventing and treating Parkinson's disease as well as a composition, application and a product thereof, and relates to the technical field of microorganisms. The invention provides three strains from human milk, namely lactobacillus helveticus LV-20, plant lactobacillus LPP8 and lactobacillus fermentum PL-15, the invention further provides a composition capable of preventing and treating the Parkinson's disease, and the three strains can well prevent and treat the Parkinson's disease and can be used for preventing and treating the Parkinson's disease. The composition can significantly improve dyskinesia (such as static tremor, muscle stiffness, movement retardation, posture balance and the like), reduce neuron damage, significantly reduce alpha-syn deposition, reverse sensory function degradation and cognitive disorder, relieve sleep disorder, inhibit neuroinflammation and oxidative stress, reduce and repair intestinal barrier damage, relieve gastrointestinal dysfunction, and improve the curative effect. As probiotics or synbiotics, products for treating and preventing Parkinson's disease have a wide application prospect.

The invention discloses an application of NeuroD1 (NeuroD1) in repairing Alzheimer's disease (Alzheimer's disease). The invention also discloses an application of the carrier for coding NeuroD1 in any one of the following aspects: preventing neuron damage and apoptosis; hippocampus atrophy is inhibited; the neuroinflammation is relieved; repairing blood vessel / blood brain barrier injury; the AD biomarker level of the cerebrospinal fluid is recovered to be normal; the removal of pathological toxic proteins in brain tissues is promoted; glucose metabolism is improved; the space working memory ability is enhanced; and regenerating neurons.

The invention discloses an application of baricitinib in treatment of cerebral arterial thrombosis, and the baricitinib is used as a neuroprotective agent and is applied to treatment of cerebral arterial thrombosis after large vascular occlusion. The application of the invention reduces neuroinflammatory response, reduces nerve injury, protects nerves, improves stroke prognosis, and improves treatment effect.

This invention relates to diselenylene-bridged mesoporous silica nanoparticles loaded with baicalin and their applications. The invention constructs a ROS-responsive, microglia-inspired Ba@Se-MSN&BV2 nanoplatform targeting the secondary phase of spinal cord injury. The BV2 cell membrane-mediated enrichment at the injury site, combined with the diselenylene-triggered, on-demand release of baicalin, enables targeted intervention in a highly oxidative and pro-inflammatory microenvironment. In vitro and in vivo studies show that Ba@Se-MSN&BV2 can alleviate oxidative stress and mitochondrial dysfunction, inhibit apoptosis, promote axonal and neuronal survival, and improve motor circuit function. This invention provides a new therapeutic target and research direction for neuroinflammatory injuries driven by redox homeostasis disruption, with significant clinical application prospects and social value.

The application discloses a new use of Leonurine or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating radiation-induced brain injury, specifically, providing a safe and effective therapeutic drug for iron death, neuroinflammation, neuron damage and lipid metabolism disorder accompanying the radiation-induced brain injury, solving the technical problem of lack of specific treatment means in the prior art, and having a wide clinical application prospect. Experiments adopt a C57BL / c mouse 30 Gy whole brain X-ray radiation model, and results show that Leonurine can significantly improve the body weight decrease and survival rate of the model mice, reduce the serum IL-6 and IFN-alpha levels, inhibit the activation of microglial cells in the cerebral cortex and hippocampus, protect and repair damaged neurons, and improve the ultrastructure of mitochondria and synapses; meanwhile, the expression of GPX4 and SLC7A11 proteins in the brain tissue is up-regulated, the GSH content is increased to inhibit iron death, and the levels of GPE, GPS and GPC related to lipid metabolism are restored.

The invention discloses a biomarker combination related to hypoxia-induced neuroinflammation and application of the biomarker combination, and belongs to the technical field of biomarker detection. The marker combination disclosed by the invention consists of serum S100 beta protein, neuron-specific enolase, interleukin-6, high-mobility group protein B1 and neurofilament light-chain protein. The marker combination can be used for stratification of nervous system injury risk of severe hypoxia patients and acquisition of prognosis evaluation data. According to the detection method disclosed by the invention, synchronous quantitative detection of five markers is realized by adopting a multiple immunofluorescent microsphere technology, and a marker combination scoring algorithm is established to comprehensively evaluate the severity of the hypoxia-related neuroinflammation.

Provided are oligomeric agents, oligomeric compounds, methods, and pharmaceutical compositions for reducing the amount or activity of IFNAR1 RNA in a cell or an animal, and in certain instances, reducing the amount of IFNAR1 protein in a cell or animal. Such oligomeric agents, oligomeric compounds, methods, and pharmaceutical compositions are useful to treat diseases and conditions associated with neuroinflammation, including Aicardi-Goutieres Syndrome, stroke, neuropsychiatric systemic lupus erythematosus, neuroinflammation following traumatic brain injury, neuro-autoimmune disorders, Alzheimer's disease, post-operative delirium and cognitive decline, cranial radiation-induced cognitive decline, viral infection-induced cognitive decline, neuromyelitis optica, and ataxia telangiectasia.

The disclosure provides methods for the acute treatment of depression and / or anxiety, for the enhancement of mTOR (e.g., mTORC1) signaling, and for the reduction of neuroinflammation, comprising administering to a patient in need thereof, a therapeutically effective amount of a 5-HT2A or 5-HT2A / D2 receptor ligand, e.g. lumateperone.

This invention discloses the application of the inflammasome NLRP6 as a target in screening drugs for treating epilepsy, and the application of NLRP6 expression inhibitors in the preparation of drugs for treating epilepsy. This invention reveals for the first time the role of the inflammasome NLRP6 in epileptic neuroinflammation. This invention identifies NLRP6 as a key regulator of neuroinflammation in epilepsy and investigates its role in activating the caspase-1 / IL-1β / IL-18 signaling pathway. Knockdown of NLRP6 can improve the damaging effects of epilepsy on neurons, thereby improving seizures; overexpression of NLRP6 may exacerbate seizures, neuronal damage, and neuroinflammatory responses. This invention provides a new potential target for epilepsy treatment, offering new research ideas and directions.